The impact of donor liver allograft fibrosis on patients undergoing liver transplantation

Vikram Wadhera, Norifumi Harimoto, Nir Lubezky, Ilias Gomatos, Matias Facciuto, David Gonzalez, Ashley Stueck, Maria Isabel Fiel, Thomas Schiano, Marcelo E. Facciuto

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: The utilization of extended criteria liver allografts (ECD) shortens time to transplantation. Objective: To characterize the effect of liver allograft fibrosis on graft and patient survival after liver transplantation (LT), with particular attention to fibrosis progression. Methods: Retrospective database search of donor and recipient liver allograft histology of liver transplants performed between 2007 and 2011. Donor and patient characteristics were analyzed. Results: One hundred and one patients underwent LT with donor liver allografts with early-stage fibrosis (stage 1 fibrosis and stage 2 fibrosis). The level of liver fibrosis did not progress in 40% of the patients tested, and there was a regression of fibrosis in 30%. At a median follow-up of 71 months, of 101 patients transplanted with fibrotic livers, 63 patients (63%) were alive with functioning initial grafts, six patients (6%) were retransplanted, and 35 patients expired. The graft survival rates were 82% and 69% at 1 and 5 years, respectively. Graft survival differences were not found to be statistically significant between the degrees of liver allograft fibrosis: 5-year graft survival (73% for stage 1 fibrosis and 62% for stage 2 fibrosis, P =.24). The entire fibrosis group was further compared with a control group of 208 consecutive primary liver transplant patients with allografts having no fibrosis. The 5-year graft survival was not significantly different between the groups (69% for the fibrosis group vs 75% for the nonfibrosis group, P =.19). Survival was also not statistically different between the groups (5-year survival of 73% for the fibrosis group vs 79% for the nonfibrosis group, P =.2). In patients with HCV, graft survival differences were not found to be statistically significant with the use of early-stage fibrotic livers: 5-year graft survival of 60% for fibrosis group vs 70% for the nonfibrosis group, P =.22). Conclusion: This study demonstrates that allografts with early-stage fibrosis achieve acceptable long-term survival after liver transplantation. Given these preliminary results, the use of organs with early-stage fibrosis warrants further studies at a larger scale to validate these results.

Original languageEnglish
Article numbere13187
JournalClinical Transplantation
Volume32
Issue number3
DOIs
Publication statusPublished - Mar 1 2018

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Transplantation

Cite this

Wadhera, V., Harimoto, N., Lubezky, N., Gomatos, I., Facciuto, M., Gonzalez, D., ... Facciuto, M. E. (2018). The impact of donor liver allograft fibrosis on patients undergoing liver transplantation. Clinical Transplantation, 32(3), [e13187]. https://doi.org/10.1111/ctr.13187